Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
James Webb Space Telescope finds strongest evidence yet for atmosphere around rocky exoplanet: 'It's really like a wet lava ball' - 2The Force of Organic product: 10 Assortments That Improve Your Wellbeing
- 3From Overpowered to Coordinated: Individual Accounts of Cleaning up
- 4Eurovision Song Contest changes voting rules after controversial allegations against Israel
- 5Machado ‘presented’ her Nobel Peace Prize medal to Trump
- 6 Famous Urban communities for Shopping on the planet
- Venice’s newest marvel is a wild, acrobatic dolphin. His refusal to leave puts him in danger
- 10 Activities to Lift Your Consume and Bust Your Stomach
- RFK Jr. releases new dietary guidelines with emphasis on protein, full-fat dairy
- Astonishing Deserts All over The Planet You Really want To Visit
- 6 Famous Urban communities for Shopping on the planet
- Well known Tea Brands for Each Tea Sweetheart
- Creative Do-It-Yourself Ventures for Each Expertise Level
- KJ Apa stars as Jimmy Stewart in new biopic: See his transformation
